Google
×
Akorn, Inc., a generic pharmaceutical company, engaged in the development, manufacture, and marketing of multi-source and branded pharmaceutical products in ...
Investors/Media: (847) 279-6162. Investor.relations@akorn.com. Akorn Receives FDA Warning Letter. LAKE FOREST, Ill., January 9, 2019 – Akorn, Inc. (Nasdaq: AKRX) ...
The Investor Relations website contains information about Akero Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports ( ...
People also ask
Mar 13, 2015 · Akorn - Investor Relations | Press Release http://investors.akorn ... (Nasdaq:AKRX), today announced the company has adopted a comprehensive ...
If you would like to report a Complaint or Adverse Event related to: Buprenorphine or Naloxone or Buprenorphine Hydrochloride - Please call 1-888-775-1770 ...
... Investor Relations page of Akorn's website for 30 days. About Akorn, Inc. Akorn, Inc. is a niche pharmaceutical company engaged in the development ...
NEW YORK, NY / ACCESSWIRE / February 21, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akorn ...
All earnings call transcripts on Akorn, Inc. (AKRXQ) stock. Read or listen to the conference call. Download the investor presentation - earnings call ...
AKRX Ticker Research. Akorn Pharmaceuticals Research Links. Akorn Pharmaceuticals Investor Relations · Yahoo Finance Page · Morningstar Page · MSN Money Page ...